Literature DB >> 574039

Production of catalepsy and depletion of brain monoamines by a butyrophenone derivative.

L D Fuenmayor, M Vogt.   

Abstract

1 The cataleptic and monoamine-depleting effects of a butyrophenone derivative (4'-fluoro-4-[[4-(p-fluorophenyl)-3-cyclohexen-1-yl]-amino]-butyrophenone hydrochloride, U-32, 802A) were studied in rats and mice and compared with those of tetrabenazine. 2 Catalepsy was evaluated by means of a modified grid test which allowed the repetition of the test in the same animal several times without affecting the results. Both drugs produced a dose-related cataleptic state of similar time course. 3 Like tetrabenazine, U-32, 802A induced a large reduction in the content of 5-hydroxytryptamine, dopamine and noradrenaline in different parts of the brain, with a concomitant elevation in the metabolites 5-hydroxyindol-3-yl acetic acid and homovanillic acid. The time courses of the catalepsy and the reduction in brain monoamines were very similar. 4 The activity of U-32, 802A suggested that the drug, although chemically a butyrophenone, might act primarily at the presynaptic organelle for storage of monoamines in a way similar to tetrabenazine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 574039      PMCID: PMC2043615     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

Authors:  A CARLSSON; M LINDQVIST
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1963

2.  MODIFICATION BY DRUGS OF THE METABOLISM OF 3,4-DIHYDROXYPHENYLETHYLAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE BRAIN.

Authors:  R LAVERTY; D F SHARMAN
Journal:  Br J Pharmacol Chemother       Date:  1965-06

3.  Influence of hypothermia on chlorpromazine-induced changes in brain amine levels.

Authors:  E COSTA; G L GESSA; B B BRODIE
Journal:  Life Sci (1962)       Date:  1962-07

4.  The neuropharmacology of trifluoperazine: a potent psychotherapeutic agent.

Authors:  D H TEDESCHI; R E TEDESCHI; L COOK; P A MATTIS; E J FELLOWS
Journal:  Arch Int Pharmacodyn Ther       Date:  1959-10-01

5.  Release of 5-hydroxytryptamine by benzoquinolizine derivatives with sedative action.

Authors:  A PLETSCHER
Journal:  Science       Date:  1957-09-13       Impact factor: 47.728

6.  Interaction of drug effects with testing procedures in the measurement of catalepsy.

Authors:  M E Stanley; S D Glick
Journal:  Neuropharmacology       Date:  1976-07       Impact factor: 5.250

7.  A benzo[a]quinolizine derivative with a neuroleptic-like action on cerebral monoamine turnover.

Authors:  A Saner; A Pletscher
Journal:  J Pharmacol Exp Ther       Date:  1977-12       Impact factor: 4.030

8.  Antagonism by amantadine of prochlorpemazine-induced catalepsy.

Authors:  P Simon; J Malatray; J R Boissier
Journal:  J Pharm Pharmacol       Date:  1970-07       Impact factor: 3.765

9.  Correlation between multitest and single test catalepsy assessment.

Authors:  B Costall; S C Hui; R J Naylor
Journal:  Neuropharmacology       Date:  1978-09       Impact factor: 5.250

10.  Effect of neuroleptics and other drugs on monoamine uptake by membranes of adrenal chromaffin granules.

Authors:  A Pletscher
Journal:  Br J Pharmacol       Date:  1977-03       Impact factor: 8.739

View more
  6 in total

1.  Parametric influences on catalepsy.

Authors:  P R Sanberg; J Pevsner; J T Coyle
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

2.  The treatment of severe dystonia in children and adults.

Authors:  C D Marsden; M H Marion; N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-11       Impact factor: 10.154

Review 3.  Neurofunctional imaging of β-cell dynamics.

Authors:  P E Harris; R L Leibel
Journal:  Diabetes Obes Metab       Date:  2012-10       Impact factor: 6.577

4.  Influence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala.

Authors:  E C Essig; I C Kilpatrick
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol.

Authors:  H L Andersen; I C Kilpatrick
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

6.  Impact of Fluoxetine on Behavioral Invigoration of Appetitive and Aversively Motivated Responses: Interaction With Dopamine Depletion.

Authors:  Carla Carratalá-Ros; Laura López-Cruz; Andrea Martínez-Verdú; Régulo Olivares-García; John D Salamone; Mercè Correa
Journal:  Front Behav Neurosci       Date:  2021-07-09       Impact factor: 3.558

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.